BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Announces Earnings Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.02, Bloomberg Earnings reports. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $5.79 million. During the same period in the previous year, the business posted ($0.22) earnings per share. BioCryst Pharmaceuticals’s revenue was down 35.4% compared to the same quarter last year.
BioCryst Pharmaceuticals (NASDAQ BCRX) opened at 5.10 on Monday. BioCryst Pharmaceuticals has a 12 month low of $3.73 and a 12 month high of $9.25. The stock has a 50 day moving average of $5.61 and a 200-day moving average of $6.36. The company’s market cap is $410.14 million.
A number of brokerages have issued reports on BCRX. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Saturday, May 6th. BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 8th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, May 19th. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $8.29.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock valued at $42,098,000 after buying an additional 1,651,292 shares during the last quarter. Bogle Investment Management L P DE acquired a new position in BioCryst Pharmaceuticals during the first quarter valued at $9,058,000. State Street Corp increased its position in BioCryst Pharmaceuticals by 55.2% in the fourth quarter. State Street Corp now owns 2,092,888 shares of the biotechnology company’s stock valued at $13,246,000 after buying an additional 744,580 shares during the last quarter. FMR LLC increased its position in BioCryst Pharmaceuticals by 97.5% in the first quarter. FMR LLC now owns 1,456,885 shares of the biotechnology company’s stock valued at $12,238,000 after buying an additional 719,162 shares during the last quarter. Finally, RA Capital Management LLC increased its position in BioCryst Pharmaceuticals by 16.7% in the first quarter. RA Capital Management LLC now owns 3,489,795 shares of the biotechnology company’s stock valued at $29,314,000 after buying an additional 500,000 shares during the last quarter. Hedge funds and other institutional investors own 84.49% of the company’s stock.
TRADEMARK VIOLATION WARNING: “BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Announces Earnings Results” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/07/biocryst-pharmaceuticals-inc-nasdaqbcrx-announces-earnings-results.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.